Producing the appropriate model and drug for intratumoural ablation

Kosmıdis, Christoforos; Sardeli, Chrysanthi; Hohenforst-Schmidt, Wolfgang; Vagionas, Anastasios; Ioannis-Katsios, Nikolaos; Sapalidis, Konstantinos

doi:10.1038/s41416-020-0895-6

Cited by 2 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have been numerous studies where ablation systems have been used along with the administration of local or systematic drugs 57 - 59 . We already have sufficient data that demonstrate the synergistic effect of ablation systems with the co-administration of drugs and this will be the future direction for research in the field of local treatment 15 , 60 - 62 .…”

Section: Discussionmentioning

confidence: 99%

Ablation for Single Pulmonary Nodules, Primary or Metastatic. Εndobronchial Ablation Systems or Percutaneous

Zarogoulidis,

Papadopoulos,

Perdikouri

et al. 2024

J. Cancer

View full text Add to dashboard Cite

Single pulmonary nodules are a difficult to diagnose imagining artifact. Currently novel diagnostic tools such as Radial-EBUS with or not C-ARM flouroscopy, electromagnetic navigation systems, robotic bronchoscopy and cone beam-compuer tomography (CBCT) can assist in the optimal guidance of biopsy equipment. After diagnosis of lung cancer or metastatic disease as pulmonary nodule, then surgery or ablation methods as local treatment can be applied. The percutaneous ablation systems under computed tomography guidance with radiofrequency, microwave, cryo and thermosphere have been used for several years. In the past 10 years extensive research has been made for endobronchial ablation systems and methods. We will present and comment on the two different ablation methods and present up to date data.

show abstract

Section: Discussionmentioning

confidence: 99%

Ablation for Single Pulmonary Nodules, Primary or Metastatic. Εndobronchial Ablation Systems or Percutaneous

Zarogoulidis,

Papadopoulos,

Perdikouri

et al. 2024

J. Cancer

View full text Add to dashboard Cite

show abstract

“…Arising from these challenges alternative methods for drug delivery, including loco-regional drug delivery, have been investigated [6,7]. Loco-regional drug delivery encompasses direct intra-tumoral (IT) or intra-lesional (IL) injection into the tumor, intra-arterial (IA) drug delivery to tumor via supplying arteries, intravesically or administration of chemotherapy to an anatomical location in close proximity to the tumor.…”

Section: Introductionmentioning

confidence: 99%

Loco-regional drug delivery in oncology: current clinical applications and future translational opportunities

Rossi

Murray

McDonough

et al. 2020

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

IntroductionDrug-based treatment regimens for cancer are often associated with off-target toxic side effects and low penetration of the drug at the tumor site leading to patient morbidity and limited efficacy. Locoregional drug delivery has the potential to increase efficacy while concomitantly reducing toxicity. Areas coveredClinical applications using loco-regional delivery include intra-arterial drug delivery in retinoblastoma, direct intra-tumoral (IT) injection of ethanol for ablation in hepatocellular carcinoma (HCC) and the use of HIPEC in peritoneal carcinomas. In recent years, there has been a significant increase in both approved products and clinical trials, with a particular emphasis on drug delivery platforms such as drug eluting beads for HCC and hydrogel platforms for intravesical delivery in bladder cancer. Expert opinionDevelopment of loco-regional drug delivery systems has been slow, limited by weak clinical data for early applications and challenges relating to dosing, delivery and retention of drugs at the site of action. However, there is increasing focus on the potential of loco-regional drug delivery when combined with bespoke drug delivery platforms. With the growth in immunotherapies, the use of IT delivery to drive priming of the anti-tumor response has opened up a new field of opportunity for locoregional drug delivery.

show abstract

Producing the appropriate model and drug for intratumoural ablation

Cited by 2 publications

References 15 publications

Ablation for Single Pulmonary Nodules, Primary or Metastatic. Εndobronchial Ablation Systems or Percutaneous

Ablation for Single Pulmonary Nodules, Primary or Metastatic. Εndobronchial Ablation Systems or Percutaneous

Loco-regional drug delivery in oncology: current clinical applications and future translational opportunities

Contact Info

Product

Resources

About